KRN8602

KRN8602 is a novel morpholino anthracycline derivative developed for its potent cytotoxic activity against both anthracycline-sensitive and resistant tumors. It acts primarily as a DNA topoisomerase II inhibitor, disrupting DNA replication and transcription in cancer cells. Preclinical studies have demonstrated significant antitumor activity in various xenograft models, including breast carcinoma. Clinically, it has shown efficacy with minimal toxicity in patients with relapsed or refractory high-grade glioma and advanced cancers. The most common dose-limiting toxicity is neutropenia; other adverse effects include gastrointestinal symptoms such as nausea and vomiting[1][4][5][7]. KRN8602 was initially developed by Kirin Holdings.

Other names

(7S,9R,10R)-3'-deamino-3'-(4-morpholinyl)-13-deoxo